a Swedish Hip Arthroplasty Register , Gothenburg , Sweden ;
b Department of Orthopaedics , Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
Acta Orthop. 2019 Jun;90(3):249-252. doi: 10.1080/17453674.2019.1599776. Epub 2019 Apr 2.
Background and purpose - The outcome of total hip arthroplasty (THA) in younger patients is suggested to be inferior compared with the general THA population. There is a lack of studies with long-term follow up for very young patients. We report on implant survival and patient-reported outcome in patients aged 30 years or younger. Patients and methods - Data on THAs performed in Sweden between the years 2000 and 2016 were included. There were 504 patients 30 years or younger with complete demographic and surgical data (study group). A matched comparison group older than 30 years was identified. Implant survival was analyzed using the Kaplan-Meier method. Patient-reported outcome was analyzed in a subgroup of patients. Results - The 10-year and 15-year implant survivorship for the study group was 90% and 78%, respectively. The corresponding figures for the patients older than 30 years were 94% and 89%. The median preoperative EQ-5D index was lower in the study group; the improvement in EQ-5D index was similar between the study and the comparison groups. The preoperative EQ-VAS was lower and the improvement in EQ-VAS at 1 year was larger in the study group. Interpretation - The promising 10-year implant survival and 1-year improvement in patient-reported outcome suggests that THA is a feasible option in the patients 30 years or younger.
背景与目的-全髋关节置换术(THA)在年轻患者中的疗效较一般 THA 患者差。目前缺乏针对非常年轻患者的长期随访研究。我们报告了年龄在 30 岁或以下的患者的植入物存活率和患者报告的结果。
患者和方法-纳入了 2000 年至 2016 年在瑞典进行的 THA 数据。有 504 名年龄在 30 岁或以下的患者具有完整的人口统计学和手术数据(研究组)。确定了一个年龄大于 30 岁的匹配对照组。使用 Kaplan-Meier 方法分析植入物存活率。在患者亚组中分析了患者报告的结果。
结果-研究组的 10 年和 15 年植入物存活率分别为 90%和 78%,而年龄大于 30 岁的患者相应的存活率分别为 94%和 89%。研究组的术前 EQ-5D 指数中位数较低;研究组和对照组的 EQ-5D 指数改善情况相似。研究组的术前 EQ-VAS 较低,术后 1 年 EQ-VAS 的改善幅度较大。
结论-有希望的 10 年植入物存活率和 1 年患者报告结果的改善表明,THA 是 30 岁或以下患者的可行选择。